Cellectis (NASDAQ:CLLS) – Analysts at Jefferies Group issued their Q1 2018 EPS estimates for shares of Cellectis in a report released on Tuesday, March 13th, Zacks Investment Research reports. Jefferies Group analyst B. Amin expects that the biotechnology company will post earnings per share of ($0.71) for the quarter. Jefferies Group also issued estimates for Cellectis’ Q2 2018 earnings at ($0.68) EPS, Q3 2018 earnings at ($0.68) EPS, FY2018 earnings at ($2.60) EPS, FY2019 earnings at ($1.72) EPS and FY2020 earnings at $1.08 EPS.
Other equities analysts also recently issued reports about the company. BidaskClub upgraded Cellectis from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 17th. ValuEngine upgraded Cellectis from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. Zacks Investment Research downgraded Cellectis from a “hold” rating to a “sell” rating in a research report on Wednesday, February 14th. Guggenheim assumed coverage on Cellectis in a research report on Friday, March 16th. They set a “neutral” rating for the company. Finally, Nomura raised their price objective on Cellectis to $73.00 and gave the stock a “buy” rating in a research report on Wednesday, March 14th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $42.67.
Cellectis stock traded down $0.17 during trading hours on Friday, hitting $28.83. The stock had a trading volume of 777,592 shares, compared to its average volume of 578,716. The company has a market capitalization of $1,035.80, a PE ratio of -10.37 and a beta of 1.86. Cellectis has a one year low of $21.25 and a one year high of $38.85.
Cellectis (NASDAQ:CLLS) last posted its earnings results on Monday, March 12th. The biotechnology company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.12). The firm had revenue of $6.91 million during the quarter, compared to the consensus estimate of $10.10 million. Cellectis had a negative net margin of 298.01% and a negative return on equity of 35.63%.
Hedge funds have recently modified their holdings of the business. JPMorgan Chase & Co. bought a new stake in Cellectis in the third quarter worth approximately $517,000. ARK Investment Management LLC increased its holdings in Cellectis by 171.7% in the fourth quarter. ARK Investment Management LLC now owns 44,382 shares of the biotechnology company’s stock worth $1,294,000 after purchasing an additional 28,048 shares in the last quarter. Hudson Bay Capital Management LP bought a new stake in Cellectis in the fourth quarter worth approximately $1,166,000. Advisors Asset Management Inc. increased its holdings in Cellectis by 1,501.1% in the third quarter. Advisors Asset Management Inc. now owns 22,592 shares of the biotechnology company’s stock worth $643,000 after purchasing an additional 21,181 shares in the last quarter. Finally, Eqis Capital Management Inc. bought a new stake in Cellectis in the fourth quarter worth approximately $748,000. Institutional investors and hedge funds own 20.31% of the company’s stock.
WARNING: This piece of content was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another website, it was stolen and reposted in violation of United States and international copyright & trademark laws. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/04/08/cellectis-sa-expected-to-post-q1-2018-earnings-of-0-71-per-share-clls.html.
Cellectis Company Profile
Cellectis SA, a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL).
Get a free copy of the Zacks research report on Cellectis (CLLS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.